Dijon Stroke Registry, E7460, Pathophysiology and Epidemiology of Cerebro-Cardiovascular Diseases (PEC2), University Hospital of Dijon, University of Burgundy, Dijon, France.
Department of Neurology, University Hospital of Dijon, Hôpital François Mitterrand, 14 rue Paul Gaffarel, BP 77908, 21079, Dijon cedex, France.
J Neurol. 2021 Mar;268(3):785-795. doi: 10.1007/s00415-019-09443-5. Epub 2019 Jun 26.
High blood pressure (BP) is the leading modifiable risk factor of stroke worldwide. Although randomized clinical trials have demonstrated the beneficial effect of BP reduction on stroke risk, there are still insufficiently explored issues concerning the optimal personalized management of BP in stroke patients in terms of thresholds to be achieved and drug classes to be prescribed. Few data are available about BP control in specific clinical contexts such as in older patients, in various stroke subtypes, or in association with co-morbidities such as diabetes. In addition, although drug trials based their conclusions on achieved mean BP values, recent findings indicate that aspects such as circadian variations of BP and BP variability should be taken into account as well. This article aims to highlight current knowledge about BP control in stroke prevention and to provide new perspectives to be addressed in future studies so as to guide clinicians in their day-to-day practice.
高血压(BP)是全球范围内导致中风的主要可改变风险因素。尽管随机临床试验已经证明了降低血压对降低中风风险的有益作用,但在中风患者的血压个性化管理方面,仍有许多未被充分探索的问题,例如要达到的阈值和要开的药物类别。关于在特定临床情况下(如老年患者、不同类型的中风或与糖尿病等合并症相关的情况下)的血压控制,数据很少。此外,尽管药物试验的结论基于所达到的平均血压值,但最近的研究结果表明,应考虑血压的昼夜变化和血压变异性等方面。本文旨在强调目前关于中风预防中血压控制的知识,并为未来研究中要解决的新问题提供新的视角,以指导临床医生的日常实践。